---

​May 2022  PRESS RELEASE

Jiangsu Hengrui Pharmaceuticals Co., Ltd. launches Luzsana Biotechnology™

---

Feb 22, 2022
​
HengRui USA Wins 2022 Top Workplaces Regional Award

---

April 27, 2021
​
HengRui USA Announces FDA Grants Orphan Drug Designation of Camrelizumab for "Treatment of Hepatocellular Carcinoma"

---

Feb 24, 2021
​
HengRui USA Announces the Launch of In-House Clinical Operations in US with 1st Subject Screened in Study Evaluating SHR-A1811 in HER2 Expressing or Mutated Advanced Malignant Solid Tumor Subject

---

Feb 05, 2021
​
HengRui USA Announces First US Patient Screened in Study Evaluating INS068 in Patients with Type 2 Diabetes Mellitus

---

Nov 28, 2020
​
HengRui USA Announces Successful Completion of Dosing in Cohort 1 in the Single Ascending Dose Trial with HRS4800

---